Antisense Therapeutics: The Emerging World Market

Published by: PJB Publications USA Inc.

Published: Apr. 1, 2002 - 200 Pages

Table of Contents

1.1 Preface

1.2 Scope of the Report

1.3 Methodology

2 Introduction

2.1 Overview of Antisense Technology

2.2 Gene Expression

2.2.1 Transcription

2.2.2 Translation

2.3 History of Antisense Drug Development

3 Antisense Technologies

3.1 Antisense Oligonucleotides

3.1.1 Mechanisms of Action


•               RNase H degradation
  
•               Inhibition of splicing
  
•               Translational arrest


3.1.2 Backbone Modification


•               Phosphorothioate oligonucleotides
  
•               Methylphosphonate oligonucleotides
  
•               Morpholino oligonucleotides
  
•               Phosphoramidate oligonucleotides
  
•               Chimeric oligonucleotides


3.1.3 Pharmacokinetics

3.1.4 Toxicity

3.1.5 Routes of Drug Delivery


•               Injection (intravenous, subcutaneous, intradermal)
  
•               Oral administration
  
•               Inhalation
  
•               Liposome encapsulation
  
•               Direct microinjection


3.1.6 Non Antisense Effects of Oligonucleotides

3.2 Peptide Nucleic Acids (PNAs)

3.3 Ribozymes

3.4 Triple Helix Oligonucleotides

3.5 Target Validation Selection of Target Site

4 Antisense Therapies

4.1 Therapeutic Advantages of Antisense Technologies

4.2 Therapeutic Applications

4.3 Antisense Therapy on the Market: Vitravene

4.4 Antisense Therapies in Development

4.4.1 Cancer


•               ISIS 3521 (Isis Pharmaceuticals)
  
•               ISIS 2503 (Isis Pharmaceuticals)
  
•               ISIS 5132 (Isis Pharmaceuticals)
  
•               AP 12009 (Antisense Pharma)
  
•               Oncomyc NG (AVI BioPharma)
  
•               AVI 4557 (AVI BioPharma)
  
•               Genasense (Genta)
  
•               GEM 231 (Hybridon)
  
•               GTI 2040 (Lorus Therapeutics)
  
•               GTI 2501 (Lorus Therapeutics)
  
•               LErafAON (NeoPharm)
  
•               PAN 346 (Panacea Pharmaceuticals)
  
•               HERZYME (Ribozyme Pharmaceuticals)
  
•               ANGIOZYME (Ribozyme Pharmaceuticals)


4.4.2 Cardiovascular Disorders


•               Resten NG (AVI BioPharma)
  
•               E2F Decoy (Corgentech)


4.4.3 Autoimmune and Inflammatory Disorders


•               ISIS 2302 (Isis Pharmaceuticals)
  
•               ISIS 104838 (Isis Pharmaceuticals)
  
•               AVI 4014 (AVI BioPharma)


4.4.4 Respiratory Disorders


•               Durason (EpiGenesis)


4.4.5 Urological Disease


•               AVI 4126 (AVI BioPharma)


4.4.6 Infectious Diseases


•               ISIS 14803 (Isis Pharmaceuticals)
  
•               HEPTAZYME (Ribozyme Pharmaceuticals)
  
•               HepBzyme (Ribozyme Pharmaceuticals)
  
•               PNAbiotics (Pantheco)
  
•               NeuBiotics (AVI BioPharma)


4.4.7 AIDS and AIDS Related Diseases


•               GEM 92 (Hybridon)
  
•               HGTV 43 (Enzo)


4.5 Competitive Environment

5 Market Analysis

5.1 Market Definition

5.2 World Market for Antisense Therapies


•           Previous market overestimations
  
•           Vitravene: a bust
  
•           Next and only drug to hit market: ISIS 3521


5.3 Antiviral Therapies

5.3.1 Incidence and Prevalence


•               HIV/AIDS
  
•               Hepatitis C


5.3.2 Current and Potential Markets


•               Vitravene


5.3.3 Antisense Competitors

5.4 Cancer Therapies

5.4.1 Incidence and Prevalence

5.4.2 Potential Market


•               ISIS 3521


5.4.3 Antisense Competitors

5.5 Cardiovascular Therapies

5.5.1 Incidence and Prevalence  


•               Coronary artery disease
  
•               Restenosis


5.5.2 Potential Market

5.5.3 Antisense Competitors

5.6 Autoimmune and Inflammatory Disease Therapies

5.6.1 Incidence and Prevalence


•               Rheumatoid arthritis
  
•               Inflammatory bowel disease
  
•               Psoriasis


5.6.2 Potential Market

5.6.3 Antisense Competitors

5.7 Respiratory Therapies

5.7.1 Incidence and Prevalence


•               Asthma


5.7.2 Potential Market

5.7.3 Antisense Competitors

6 Company Briefs

7 Company Directory

List of Figures

Figure 5.1 World Market Size and Growth of Antisense Drugs 2001-2006

Figure 5.2 World Market Size and Growth of Antisense Antiviral Drugs 2001-2006

Figure 5.3 World Market Size and Growth of Antisense Cancer Drugs 2001-2006

List of Tables

4 1 Selected Antisense Drugs in Development 2002

Table 5 1 World Market Size and Growth of Antisense Drugs 2001-2006

Table 5 2 World Market Size and Growth of Antisense Antiviral Drugs 2001-2006

Table 5 3 World Market Size and Growth of Antisense Cancer Drugs 2001-2006

Abstract

But: is this excitement premature? Has Wall Street over-hyped this technology’s short-term commercial potential? Antisense Therapeutics: The Emerging World Market analyzes the current state of clinical trials as well as recent actual sales figures to bring you an accurate analysis of this market to 2006. Key questions answered include:

Commercial potential

• Which compounds will really reach market by 2006?
• What is their real sales potential?
• How can you separate the truth from the hype?

Compounds in development

• What compounds are currently in human clinical trials?
• What compounds will reach the clinical trial stage in the next five years?

Companies

• Which companies are investing in antisense technology?
• How are they developing and exploiting it?

Antisense technology is still in its infancy, and has nearly unlimited therapeutic and commercial potential. Find out when this potential will be realized.

Please Note: Theta requires that, for PDF orders, clients sign a confidentiality agreement prior to fulfillment of PDF email delivery.

Get Full Details About This Report >>

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.